Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients
Tóm tắt
In response to reactive oxygen species (ROS), thioredoxin and DJ-1 are upregulated to counteract the detrimental effect of ROS under normal condition. However, cancer cells can take advantage of thioredoxin and DJ-1 against ROS-induced cell damage. In several human cancer types, thioredoxin and DJ-1 were found to be overexpressed. The present study aimed to explore the serum levels of thioredoxin and DJ-1 in non-small cell lung cancer (NSCLC) patients and its relationship to the diagnosis and prognosis of this particular malignancy. Sera from 134 NSCLC patients and 168 healthy controls were obtained. Using the enzyme-linked immunosorbent assay (ELISA) method, the levels of serum thioredoxin and DJ-1 were measured and correlated to the clinicopathological characteristics of NSCLC patients. The diagnostic and prognostic significance of the biomarkers were evaluated by using receiver operating curve (ROC), Kaplan–Meier curve, and log-rank analyses and the Cox proportional hazard model, respectively. Serum thioredoxin and DJ-1 levels were significantly higher in the NSCLC patients than that in the controls (23.5 ± 6.57 vs. 13.8 ± 2.49 and 7.11 ± 2.02 vs. 5.18 ± 1.26, respectively). NSCLC patients at later stage cancer showed significantly higher levels of serum thioredoxin and DJ-1 than those at the early stages (P < 0.01 and P < 0.05, respectively). Multivariate logistic regression analysis showed that high serum thioredoxin level was an independent risk factor for lymph nodal metastases and distant metastases (OR = 2.18, 95 % CI 1.26–3.41 and OR = 3.68, 95 % CI 2.16–5.33, respectively). In addition, an increase in the serum DJ-1 level was also identified as an independent risk factor for nodal metastases (OR = 1.37, 95 % CI 1.11–3.04). For predicting the development of NSCLC, ROC/area under the curve (AUC) analysis for thioredoxin indicated an AUC of 0.80 (sensitivity 0.62, specificity 0.92), and ROC/AUC analysis for DJ-1 showed an AUC of 0.78 (sensitivity 0.66, specificity 0.89). NSCLC patients with high serum thioredoxin and DJ-1 levels had lower survival rates than those with low levels, and multivariate analyses for overall survival revealed that high serum thioredoxin levels served as an independent prognostic factor for NSCLC (HR = 2.07, 95 % CI 1.19–3.48). Serum levels of thioredoxin and DJ-1 were significantly higher in NSCLC patients; therefore, these may be utilized as novel diagnostic and prognostic biomarkers for NSCLC.
Tài liệu tham khảo
Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015;4:36–54.
Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA: Cancer J Clin. 2012;62:220–41.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–94.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: Cancer J Clin. 2012;62:10–29.
Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol. 1997;82:291–5.
Nogueira V, Hay N. Molecular pathways: reactive oxygen species homeostasis in cancer cells and implications for cancer therapy. Clinical Cancer Res: Off J Am Assoc Cancer Res. 2013;19:4309–14.
Bertini R, Howard OM, Dong HF, Oppenheim JJ, Bizzarri C, Sergi R, et al. Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and t cells. J Exp Med. 1999;189:1783–9.
Kondo N, Nakamura H, Masutani H, Yodoi J. Redox regulation of human thioredoxin network. Antioxid Redox Signal. 2006;8:1881–90.
Kasuno K, Nakamura H, Ono T, Muso E, Yodoi J. Protective roles of thioredoxin, a redox-regulating protein, in renal ischemia/reperfusion injury. Kidney Int. 2003;64:1273–82.
Kato A, Odamaki M, Nakamura H, Yodoi J, Hishida A. Elevation of blood thioredoxin in hemodialysis patients with hepatitis c virus infection. Kidney Int. 2003;63:2262–8.
Abdiu A, Nakamura H, Sahaf B, Yodoi J, Holmgren A, Rosen A. Thioredoxin blood level increases after severe burn injury. Antioxid Redox Signal. 2000;2:707–16.
Jikimoto T, Nishikubo Y, Koshiba M, Kanagawa S, Morinobu S, Morinobu A, et al. Thioredoxin as a biomarker for oxidative stress in patients with rheumatoid arthritis. Mol Immunol. 2002;38:765–72.
Kishimoto C, Shioji K, Nakamura H, Nakayama Y, Yodoi J, Sasayama S. Serum thioredoxin (trx) levels in patients with heart failure. Jpn Circ J. 2001;65:491–4.
Tsuchikura S, Shoji T, Shimomura N, Kakiya R, Emoto M, Koyama H, et al. Serum c-reactive protein and thioredoxin levels in subjects with mildly reduced glomerular filtration rate. BMC Nephrol. 2010;11:7.
Li J, Cheng ZJ, Liu Y, Yan ZL, Wang K, Wu D, et al. Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma. Oncotarget. 2015;6:9551–63.
Nakamura H, Bai J, Nishinaka Y, Ueda S, Sasada T, Ohshio G, et al. Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect Prev. 2000;24:53–60.
Raninga PV, Trapani GD, Tonissen KF. Cross talk between two antioxidant systems, thioredoxin and dj-1: consequences for cancer. Oncoscience. 2014;1:95–110.
Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K, Ariga H. Dj-1 has a role in antioxidative stress to prevent cell death. EMBO Rep. 2004;5:213–8.
Kapoor S. Dj-1 and its emerging role as a biomarker of systemic malignancies besides lung carcinomas. Mol Biol Rep. 2013;40:1529.
Chen LL, Tian JJ, Su L, Jing Y, Zhang SC, Zhang HX, et al. Dj-1: a promising marker in metastatic uveal melanoma. J Cancer Res Clin Oncol. 2015;141:315–21.
Kawate T, Iwaya K, Koshikawa K, Moriya T, Yamasaki T, Hasegawa S, et al. High levels of dj-1 protein and isoelectric point 6.3 isoform in sera of breast cancer patients. Cancer Sci 2015.
Bai J, Guo C, Sun W, Li M, Meng X, Yu Y, et al. Dj-1 may contribute to metastasis of non-small cell lung cancer. Mol Biol Rep. 2012;39:2697–703.
Kim RH, Peters M, Jang Y, Shi W, Pintilie M, Fletcher GC, et al. Dj-1, a novel regulator of the tumor suppressor pten. Cancer Cell. 2005;7:263–73.
MacKeigan JP, Clements CM, Lich JD, Pope RM, Hod Y, Ting JP. Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of rs/dj-1 and rhogdialpha. Cancer Res. 2003;63:6928–34.
Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, et al. Pd-l1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer 2015
Feng B, Zhang K, Wang R, Chen L. Non-small-cell lung cancer and mirnas: novel biomarkers and promising tools for treatment. Clin Sci. 2015;128:619–34.
Brega E, Brandao G. Non-small cell lung carcinoma biomarker testing: the pathologist’s perspective. Front Oncol. 2014;4:182.
Robbins D, Zhao Y. Oxidative stress induced by mnsod-p53 interaction: pro- or anti-tumorigenic? J Signal Transduct. 2012;2012:101465.
Martindale JL, Holbrook NJ. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol. 2002;192:1–15.
Kabe Y, Ando K, Hirao S, Yoshida M, Handa H. Redox regulation of nf-kappab activation: distinct redox regulation between the cytoplasm and the nucleus. Antioxid Redox Signal. 2005;7:395–403.
Ryter SW, Kim HP, Hoetzel A, Park JW, Nakahira K, Wang X, et al. Mechanisms of cell death in oxidative stress. Antioxid Redox Signal. 2007;9:49–89.
Kim SJ, Miyoshi Y, Taguchi T, Tamaki Y, Nakamura H, Yodoi J, et al. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clinical Cancer Res: Off J Am Assoc Cancer Res. 2005;11:8425–30.
He T, Banach-Latapy A, Vernis L, Dardalhon M, Chanet R, Huang ME. Peroxiredoxin 1 knockdown potentiates beta-lapachone cytotoxicity through modulation of reactive oxygen species and mitogen-activated protein kinase signals. Carcinogenesis. 2013;34:760–9.
Ueno M, Masutani H, Arai RJ, Yamauchi A, Hirota K, Sakai T, et al. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem. 1999;274:35809–15.
Schenk H, Klein M, Erdbrugger W, Droge W, Schulze-Osthoff K. Distinct effects of thioredoxin and antioxidants on the activation of transcription factors nf-kappa b and ap-1. Proc Natl Acad Sci U S A. 1994;91:1672–6.
Park BJ, Cha MK, Kim IH. Thioredoxin 1 as a serum marker for breast cancer and its use in combination with cea or ca15-3 for improving the sensitivity of breast cancer diagnoses. BMC Res Notes. 2014;7:7.
Park BJ, Cha MK, Kim IH. Thioredoxin 1 as a serum marker for ovarian cancer and its use in combination with ca125 for improving the sensitivity of ovarian cancer diagnoses. Biomark: Biochem Indic Expo Response Susceptibility Chem. 2014;19:604–10.
Cao J, Lou S, Ying M, Yang B. Dj-1 as a human oncogene and potential therapeutic target. Biochem Pharmacol. 2015;93:241–50.
Zhou W, Freed CR. Dj-1 up-regulates glutathione synthesis during oxidative stress and inhibits a53t alpha-synuclein toxicity. J Biol Chem. 2005;280:43150–8.
Yang Y, Gehrke S, Haque ME, Imai Y, Kosek J, Yang L, et al. Inactivation of drosophila dj-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/akt signaling. Proc Natl Acad Sci U S A. 2005;102:13670–5.
Vasseur S, Afzal S, Tardivel-Lacombe J, Park DS, Iovanna JL, Mak TW. Dj-1/park7 is an important mediator of hypoxia-induced cellular responses. Proc Natl Acad Sci U S A. 2009;106:1111–6.
Shinbo Y, Taira T, Niki T, Iguchi-Ariga SM, Ariga H. Dj-1 restores p53 transcription activity inhibited by topors/p53bp3. Int J Oncol. 2005;26:641–8.
Zeng HZ, Qu YQ, Zhang WJ, Xiu B, Deng AM, Liang AB. Proteomic analysis identified dj-1 as a cisplatin resistant marker in non-small cell lung cancer. Int J Mol Sci. 2011;12:3489–99.
Zhou C. Lung cancer molecular epidemiology in china: recent trends. Transl Lung Cancer Res. 2014;3:270–9.
Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, et al. Serum dkk1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012;13:817–26.